Valuation: Armata Pharmaceuticals, Inc.

Market Cap 13Cr 11Cr 11Cr 9.6Cr 18Cr 1.22TCr 18Cr 127.26Cr 50Cr 636.61Cr 48Cr 47Cr 2.02TCr P/E 2026 *
-1.85x
P/E 2027 * -2.39x
Enterprise Value 13Cr 11Cr 11Cr 9.6Cr 18Cr 1.22TCr 18Cr 127.26Cr 50Cr 636.61Cr 48Cr 47Cr 2.02TCr EV / Sales 2026 *
30.2x
EV / Sales 2027 * 46.6x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day+12.75%
1 week+11.65%
Current month-5.99%
1 month-17.86%
3 months-34.16%
6 months-75.20%
Current year-45.06%
1 week 2.94
Extreme 2.935
3.5
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/07/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/04/26 Free

Director

51,280 0.1400%
14/03/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+12.75%+11.65%-51.06%+74.24% 13Cr
-4.10%-8.54%+40.05%+66.99% 6.33TCr
-0.66%+6.93%+10.42%+72.54% 5.49TCr
-0.03%+3.94%+9.37%+91.64% 5.33TCr
+0.61%+2.69%+27.75%+50.97% 4.58TCr
-1.08%+2.19%+21.92%+131.38% 4.35TCr
-3.39%-0.83%+254.27%+571.04% 4.02TCr
-1.67%+6.70%+14.42%+56.67% 3.35TCr
+1.19%-4.98%+29.01%-0.76% 2.37TCr
-1.17%+4.88%+35.40%+26.58% 2.38TCr
Average +0.24%+1.58%+39.15%+114.13% 3.82TCr
Weighted average by Cap. -1.33%+0.60%+47.29%+122.09%

Financials

2026 *2027 *
Net sales 42.5L 37.94L 35L 31.8L 59.65L 40Cr 60.57L 4.22Cr 1.66Cr 21Cr 1.6Cr 1.56Cr 67Cr 27.5L 24.55L 22.65L 20.57L 38.6L 26Cr 39.19L 2.73Cr 1.07Cr 14Cr 1.03Cr 1.01Cr 43Cr
Net income -7.66Cr -6.84Cr -6.31Cr -5.73Cr -11Cr -725.59Cr -11Cr -76Cr -30Cr -380.15Cr -29Cr -28Cr -1.2TCr -7.2Cr -6.43Cr -5.93Cr -5.39Cr -10Cr -682.01Cr -10Cr -71Cr -28Cr -357.32Cr -27Cr -26Cr -1.13TCr
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
22/26/22 $3.450 +12.75% 1,07,994
21/26/21 $3.060 -4.38% 93,557
20/26/20 $3.200 +4.23% 87,387
19/26/19 $3.070 -8.90% 88,261
16/26/16 $3.370 +9.06% 1,54,319
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.450USD
Average target price
17.50USD
Spread / Average Target
+407.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock